Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

175
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
175
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

270
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
270
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

169
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
169
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

68
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
68
Long-term Depression01:05

Long-term Depression

31.0K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
31.0K
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

137
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
137

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

α<sub>2</sub>-Adrenergic receptor modulates 5-HT<sub>2A</sub>-mediated behavioral effects of MDMA and psilocybin in mice.

Molecular psychiatry·2026
Same author

Reply to "Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies".

Journal of clinical psychopharmacology·2026
Same author

Reducing Chronic Pain With Transcranial Direct Current Stimulation in Veterans Engaged in Intensive Outpatient Mental Health Treatment: A Pilot Study.

Military medicine·2026
Same author

Whole-blood transcriptomic response to whole-body hyperthermia in participants with major depressive disorder.

Brain, behavior, & immunity - health·2026
Same author

Age-dependent acceleration of structural brain aging in medication-free major depressive disorder linked to neuroanatomical phenotype findings from COORDINATE-MDD consortium.

medRxiv : the preprint server for health sciences·2026
Same author

The association between obsessive-compulsive symptoms and self-compassion: A meta-analysis and systematic review.

Journal of affective disorders·2026

Related Experiment Video

Updated: Jul 17, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.0K

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.

Charles L Raison1, Gerard Sanacora2, Joshua Woolley3,4

  • 1Usona Institute, Fitchburg, Wisconsin.

JAMA
|August 31, 2023
PubMed
Summary

Psilocybin significantly reduced depression symptoms and functional disability in adults with major depressive disorder (MDD) compared to niacin placebo over 43 days. This study supports psilocybin as a promising novel intervention for MDD when combined with psychological support.

More Related Videos

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.3K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.6K

Related Experiment Videos

Last Updated: Jul 17, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.0K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.3K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.6K

Area of Science:

  • Psychiatry and Neuroscience
  • Clinical Psychology
  • Pharmacology

Background:

  • Major depressive disorder (MDD) is a leading cause of disability worldwide.
  • Current treatments for MDD have limitations in efficacy and tolerability.
  • Psilocybin, a psychedelic compound, has shown potential for rapid and sustained antidepressant effects.

Purpose of the Study:

  • To evaluate the efficacy and safety of a single dose of psilocybin in patients with MDD.
  • To assess the magnitude, timing, and durability of antidepressant effects.
  • To compare psilocybin's effects against a niacin placebo with psychological support.

Main Methods:

  • A phase 2, randomized, double-blind, placebo-controlled trial involving 104 adults with MDD.
  • Participants received either a 25-mg dose of psilocybin or a niacin placebo, both with psychological support.
  • Primary outcome was change in Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline to day 43.

Main Results:

  • Psilocybin treatment led to significantly greater reductions in MADRS scores compared to niacin at both day 43 (mean difference: -12.3) and day 8 (mean difference: -12.0).
  • Significant improvements were also observed in functional disability as measured by the Sheehan Disability Scale.
  • While no serious adverse events were reported, psilocybin was associated with a higher rate of overall and severe adverse events.

Conclusions:

  • A single dose of psilocybin, administered with psychological support, demonstrated a clinically significant and sustained reduction in depressive symptoms and functional impairment in patients with MDD.
  • These findings reinforce the potential of psilocybin as a novel therapeutic option for MDD.
  • Further research is warranted to optimize dosing and understand long-term effects and safety profiles.